January 3, 2020
Authored and Edited by Michael Liu Su; Samhitha Muralidhar Medatia; Elizabeth D. Ferrill
In Amgen Inc. v. Hospira, Inc., Nos. 2019-1067 and 2019-1102 (Fed. Cir. Dec. 16, 2019), the Federal Circuit affirmed the district court’s denial of the parties’ motions for JMOL or alternative motions for new trial, regarding infringement, invalidity, § 271(e)(1) Safe Harbor, and damages.
Regarding Safe Harbor, Hospira challenged the jury instructions, which indicated that manufacturing a batch of a particular drug was protected by the Safe Harbor provision if it was “reasonably related” to submitting information to the FDA to obtain approval. The Federal Circuit, however, found no legal error. It reasoned that because the accused activity is Hospira’s use of Amgen’s claimed methods of manufacture, the relevant inquiry is not how Hospira used each batch it manufactured, but whether each act of manufacture was for uses reasonably related to submitting information to the FDA.
Hospira also contended that no reasonable jury could have found that some, but not all, of Hospira’s batches were protected by the Safe Harbor. But the Federal Circuit upheld the jury’s finding based on substantial evidence.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
INCONTESTABLE® Blog
The Federal Circuit’s Heartfelt Affirmation of Everybody’s Right to Use “Everybody vs. Racism”
March 22, 2024
Federal Circuit IP Blog
March 21, 2024
Ad Law Buzz Blog
“Banning” a Banned Ingredients Claim: NAD’s Application (and Expansion) of the FTC’s Green Guides
March 18, 2024
Federal Circuit IP Blog
Prior Printed Publications “Publicly Available” Despite Confidentiality Restrictions
March 7, 2024
INCONTESTABLE® Blog
E.D. Pa. Delivers Summary Judgment Victory in Row Over Meta Tags
February 22, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.